Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 364268
The Licensee exercised the Topical BETi Option, granting Licensee a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Licensorâ€™s BETi compounds identified to be suitable for topical administration in all fields. The Licensee has the sole responsibility for development, regulatory, marketing and commercialization activities to be conducted for the licensed topical products.
The agreement relates to the discovery and development of proprietary Bromodomain and Extra-Terminal Domain inhibitors (â€œBET inhibitorâ€ or â€œBETiâ€) for the treatment of immunology and oncology conditions.
IPSCIO Record ID: 183244
This agreement is for the pharmaceutical industry, excluding oncology use.
IPSCIO Record ID: 369281
The BET inhibitor program is from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.
There is emerging preclinical data showing BET inhibitors may enhance the activity of immuno-oncology agents, such as anti-PD-1/PD-L1 antibodies, providing multiple opportunities for us to combine this novel mechanism within our portfolio. Epigenetic targeted agents, especially BET inhibitors, have been an area of great interest of ours for some time and are particularly attractive to us because of their effects on c-Myc driven tumors, like aggressive GCB-subtype DLBCL, an area we have seen early activity with TGR-1202 and our proprietary combination referred to as TG-1303.
Field means all prophylactic, palliative, therapeutic or diangnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemiaâ€™s, Lymphomaâ€™s, Multipe Myeloma and Waldenstromâ€™s Macroglobulinemia.